Is your company currently looking to establish or increase vaccine manufacturing capacity? The race to meet demand for COVD-19 vaccines (and therapies) has dramatically reshaped the planning and execution of pharmaceutical manufacturing capital projects. And when it comes to vaccines, a proper understanding of the specific synthesis and formulation processes involved – and the current challenges therein – is essential for success. Without it, capital projects cannot be executed on time or budget in this highly challenging and dynamic environment.
In this second installment of the multi-part webinar series, we review the synthesis and formulation processes for the various vaccine types and do a deep-dive on mRNA and DNA vaccines. We outline the implications for any company currently looking to establish or increase manufacturing capacity for mRNA and DNA vaccines.
Join our subject matter expert Christian Lavarreda on this second installment of "Vaccine Synthesis and Formulation Processes" on Thursday, July 29, 2021. This event will last approximately 45 minutes and include an interactive Q&A session.